

Ref: MHL/Sec&Legal/2020-21/171

Date: February 10, 2021

To,  
**Head, Listing Compliance Department**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai - 400 001.

**Head, Listing Compliance Department**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051.  
**Scrip Symbol: METROPOLIS**

**Scrip Code: 542650**

**Sub: Outcome of Board Meeting held on Wednesday, February 10, 2021**

**Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR')**

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at their meeting held today have *inter-alia*:

- i. Approved the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Statements of the Company for the quarter and nine months ended December 31, 2020.

The copy of the Unaudited Standalone & Consolidated Financial Statements of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and nine months ended December 31, 2020 is enclosed as **Annexure – 1**.

- ii. Approved the re-appointment of Ms. Ameera Sushil Shah as the Managing Director, for a period of five years with effect from March 18, 2021, as per the recommendation of the Nomination and Remuneration Committee, subject to approval of members of the Company at the ensuing Annual General Meeting.

The necessary details as required pursuant to Regulation 30 of SEBI LODR read with SEBI Circular CIR/CFD/CMD/4/2015 are enclosed as **Annexure – 2**.

- iii. Approved and declared payment of Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per equity share on the Face Value Rs. 2 (Rupees Two only) each for the financial year 2020-2021. The interim dividend will be paid to the members whose names appear in the Register of Members / Register of beneficiaries as on the 'Record Date' i.e. February 19, 2021. The Interim Dividend will be paid to the shareholders within 30 days of declaration.

**BLOOD TESTS • DIAGNOSTICS • WELLNESS**

**METROPOLIS**  
The Pathology Specialist

**Metropolis Healthcare Limited**

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [support@metropolisindia.com](mailto:support@metropolisindia.com)

Website: [www.metropolisindia.com](http://www.metropolisindia.com)

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

- iv. Approved the change in constitution of the Nomination and Remuneration Committee of the Company with effect from February 10, 2021. The details of change in the Committee constitution is enclosed as **Annexure – 3**.

The meeting commenced at 2:00 p.m. and concluded at 4:10 p.m.

Thanking you,  
Yours faithfully

For **Metropolis Healthcare Limited**



Poonam Tanwani  
**Company Secretary & Compliance Officer**  
Membership No. A19182  
Encl. a/a

**BLOOD TESTS • DIAGNOSTICS • WELLNESS**

**METROPOLIS**  
The Pathology Specialist

**Metropolis Healthcare Limited**

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [support@metropolisindia.com](mailto:support@metropolisindia.com)

Website: [www.metropolisindia.com](http://www.metropolisindia.com)

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.